The EFNB3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal HeLa cell population with targeted EFNB3 gene disruption, eliminating functional ephrin-B3 expression. This heterogeneous knockout model enables population-level loss-of-function studies of ephrin-B3’s tumor-suppressive and axon guidance roles, without requiring clonal selection.
The host HeLa cell line is an HPV18-positive, immortalized human cervical adenocarcinoma epithelial line widely employed in cancer research, signal transduction, and drug discovery. Its epithelial origin and transformed phenotype render it appropriate for investigating carcinoma progression, cell adhesion, and migration.
Ephrin-B3 (EFNB3) functions as a transmembrane ligand for EphB receptor tyrosine kinases (EPHB1, EPHB2, EPHB3, EPHB4). Ligand-receptor interaction triggers bidirectional signaling: forward signaling through EphB kinase activity recruits Src family kinases, FAK, and the Rho family GTPases RhoA, Rac1, and Cdc42, which collectively orchestrate cytoskeletal rearrangements. Downstream effectors include PAK and Grb4, linking to PI3K-Akt and cell adhesion molecule pathways. Reverse signaling mediated by the ephrin-B3 cytoplasmic tail modulates integrin function, serving tumor-suppressive roles in epithelial tissues by restricting migration and invasion. Upstream transcriptional regulators such as PAX6 and SOX2, along with Wnt and FGF signaling cascades, control EFNB3 expression levels.
In the HeLa cervical adenocarcinoma context, ablation of EFNB3 eliminates ephrin-B3?CEphB repulsive cues, potentially releasing constraints on cell motility and fostering invasive phenotypes. As a putative tumor suppressor, ephrin-B3 loss in these epithelial cancer cells provides a direct model to examine how disrupted Eph/ephrin signaling contributes to tumor progression, altered adhesion dynamics, and aberrant survival signaling. The polyclonal knockout population recapitulates the genetic heterogeneity inherent to tumors, making it ideal for studying variable responses to pathway perturbations and therapeutic interventions.
These polyclonal knockout cells are suited for diverse experimental workflows. Migration and invasion can be assessed via wound healing/scratch assays and transwell assays, while immunofluorescence enables visualization of EphB receptor distribution. Protein interaction studies using co-immunoprecipitation can detect ephrin-B3?CEphB complexes, and western blotting for EphB phospho-tyrosine provides insight into receptor activation status. Gene expression changes can be profiled by RT-qPCR and RNA-seq. Additional applications include apoptosis assays, cell adhesion assessments, and pharmaceutical targeting of the Eph/ephrin axis. For custom inquiries, contact Ascent Research.
